This live session took place on Thursday, October 19th, 2017.

There are a number of reasons, including rising disease prevalence, an improved regulatory environment, and emerging product innovation, that account for the accelerated growth in the U.S. market for diabetes devices. Bloomberg Intelligence and Decision Resources Group recently co-hosted a webinar discussion on emerging diabetes device therapies and the impact of Medicare coverage on the industry. Fill in the form to gain immediate access to the webinar recording.

Our analysts discussed:
• Factors behind the increase in the diabetes disease rate
• The improved regulatory environment, including increased coverage for type 2 patients
• Innovation in the market from some of the top companies, including:
- Medtronic’s 670G closed-loop artificial pancreas
- Addition of Bluetooth technology to existing products from Sanofi, Medtronic, Dexcom and Roche
- DexCom's G5 Mobile approval for Medicare diabetes patients
- Other improved and emerging products in the pipeline

Meet our analysts:

  Jason McGorman, Senior Equity Analyst, Health Care
Bloomberg Intelligence
Jason covers the health care sector, including medical devices, hospitals, and health insurance providers. He holds a BS in finance from Liberty University, is a CFA charterholder, and is currently pursuing his Master of Business Administration at Duke University’s Fuqua School of Business through its Global Executive program.
Paul Desormeaux, Senior Analysts, MedTech Insights
Decision Resources Group
Paul is the authority on neurosurgery, neurostimulation, obesity, and diabetes markets at DRG. He holds a B.Sc. from Queen’s University and a M.Sc. from Western University in biochemistry.

How Glympse Bio oversubscribed their Series B funding amidst the pandemic

View Now